Skip to main content
Erschienen in: Pediatric Cardiology 5/2012

01.06.2012 | Original Article

Impact of Sildenafil on Echocardiographic Indices of Myocardial Performance After the Fontan Operation

verfasst von: David J. Goldberg, Benjamin French, Anita L. Szwast, Michael G. McBride, Bradley S. Marino, Nicole Mirarchi, Brian D. Hanna, Gil Wernovsky, Stephen M. Paridon, Jack Rychik

Erschienen in: Pediatric Cardiology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was describe the impact of sildenafil on echocardiographic measures of myocardial performance in children and young adults with a functional single-ventricle physiology late after Fontan surgery. A double-blind, placebo-controlled, crossover trial was conducted in children and young adults after the Fontan operation at a single pediatric center. Subjects were randomized to receive placebo or sildenafil (20 mg tid) for 6 weeks. After a 6-week washout period, subjects were crossed for an additional 6 weeks. Each subject underwent an echocardiogram at the start and finish of each phase. A total of 27 subjects completed study testing at a mean age of 14.9 years and a mean time from Fontan surgery of 11.3 years. After sildenafil, subjects demonstrated improvement in their myocardial performance index (MPI; −0.051; 95% CI −0.095, −0.0077; p 0.02) and in the product of the velocity time integral (VTI) of the dominant outflow tract and the heart rate (HR; 110 cm × bpm; 95% CI 7.5, 220; p = 0.04). Measures of diastolic performance, including inflow velocities, myocardial velocities, and the ratio of blood pool velocity to myocardial velocity during passive inflow, did not change. In this cohort, there were significant improvements in both the MPI and the product of the VTI × HR after 6 weeks of treatment with sildenafil. These findings suggest that sildenafil may be a useful therapy to improve or maintain ventricular performance in select patients after the Fontan operation.
Literatur
1.
Zurück zum Zitat Anderson PA, Sleeper LA, Mahony L, Colan SD, Atz AM, Breitbart RE et al (2008) Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. J Am Coll Cardiol 52:85–98PubMedCrossRef Anderson PA, Sleeper LA, Mahony L, Colan SD, Atz AM, Breitbart RE et al (2008) Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. J Am Coll Cardiol 52:85–98PubMedCrossRef
2.
Zurück zum Zitat Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N (2008) Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 14:189–197PubMedCrossRef Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N (2008) Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 14:189–197PubMedCrossRef
3.
Zurück zum Zitat Caldas MC, Meira ZA, Barbosa MM (2008) Evaluation of 107 patients with sickle cell anemia through tissue Doppler and myocardial performance index. J Am Soc Echocardiogr 21:1163–1167PubMedCrossRef Caldas MC, Meira ZA, Barbosa MM (2008) Evaluation of 107 patients with sickle cell anemia through tissue Doppler and myocardial performance index. J Am Soc Echocardiogr 21:1163–1167PubMedCrossRef
4.
Zurück zum Zitat Canter CE, Shaddy RE, Bernstein D, Hsu DT, Chrisant MR, Kirklin JK et al (2007) Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 115:658–676PubMedCrossRef Canter CE, Shaddy RE, Bernstein D, Hsu DT, Chrisant MR, Kirklin JK et al (2007) Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 115:658–676PubMedCrossRef
5.
Zurück zum Zitat Cheung EW, Lam WW, Cheung SC, Cheung YF (2008) Functional implications of the right ventricular myocardial performance index in patients after surgical repair of tetralogy of Fallot. Heart Vessels 23:112–117PubMedCrossRef Cheung EW, Lam WW, Cheung SC, Cheung YF (2008) Functional implications of the right ventricular myocardial performance index in patients after surgical repair of tetralogy of Fallot. Heart Vessels 23:112–117PubMedCrossRef
6.
Zurück zum Zitat Diller GP, Giardini A, Dimopoulos K, Gargiulo G, Muller J, Derrick G et al (2010) Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. Eur Heart J 31(24):3073–3083PubMedCrossRef Diller GP, Giardini A, Dimopoulos K, Gargiulo G, Muller J, Derrick G et al (2010) Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. Eur Heart J 31(24):3073–3083PubMedCrossRef
8.
Zurück zum Zitat Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD et al (2011) Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation 123:1185–1193PubMedCrossRef Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD et al (2011) Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation 123:1185–1193PubMedCrossRef
9.
Zurück zum Zitat Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) PDE5-inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry and clinical status in patients with stable systolic heart failure: results of a 1-year prospective, randomized, placebo-controlled study. Circ Heart Fail 4(1):8–17PubMedCrossRef Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) PDE5-inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry and clinical status in patients with stable systolic heart failure: results of a 1-year prospective, randomized, placebo-controlled study. Circ Heart Fail 4(1):8–17PubMedCrossRef
10.
Zurück zum Zitat Jenkins PC, Chinnock RE, Jenkins KJ, Mahle WT, Mulla N, Sharkey AM et al (2008) Decreased exercise performance with age in children with hypoplastic left heart syndrome. J Pediatr 152:507–512PubMedCrossRef Jenkins PC, Chinnock RE, Jenkins KJ, Mahle WT, Mulla N, Sharkey AM et al (2008) Decreased exercise performance with age in children with hypoplastic left heart syndrome. J Pediatr 152:507–512PubMedCrossRef
11.
Zurück zum Zitat Kenward MG, Roger JH (2010) The use of baseline covariates in crossover studies. Biostatistics 11:1–17PubMedCrossRef Kenward MG, Roger JH (2010) The use of baseline covariates in crossover studies. Biostatistics 11:1–17PubMedCrossRef
12.
Zurück zum Zitat Klimes K, Ovroutski S, Abdul-Khaliq H, Ewert P, Alexi-Meskishvili V, Kuehne T et al (2009) Exercise capacity reflects ventricular function in patients having the Fontan circulation. Cardiol Young 19(4):340–345PubMedCrossRef Klimes K, Ovroutski S, Abdul-Khaliq H, Ewert P, Alexi-Meskishvili V, Kuehne T et al (2009) Exercise capacity reflects ventricular function in patients having the Fontan circulation. Cardiol Young 19(4):340–345PubMedCrossRef
13.
Zurück zum Zitat Kreutzer G, Galindez E, Bono H, De Palma C, Laura JP (1973) An operation for the correction of tricuspid atresia. J Thorac Cardiovasc Surg 66:613–621PubMed Kreutzer G, Galindez E, Bono H, De Palma C, Laura JP (1973) An operation for the correction of tricuspid atresia. J Thorac Cardiovasc Surg 66:613–621PubMed
14.
Zurück zum Zitat Lai WW, Geva T, Shirali GS, Frommelt PC, Humes RA, Brook MM et al (2006) Guidelines and standards for performance of a pediatric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography. J Am Soc Echocardiogr 19:1413–1430PubMedCrossRef Lai WW, Geva T, Shirali GS, Frommelt PC, Humes RA, Brook MM et al (2006) Guidelines and standards for performance of a pediatric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography. J Am Soc Echocardiogr 19:1413–1430PubMedCrossRef
15.
Zurück zum Zitat Morner S, Lindqvist P, Waldenstrom A, Kazzam E (2008) Right ventricular dysfunction in hypertrophic cardiomyopathy as evidenced by the myocardial performance index. Int J Cardiol 124:57–63PubMedCrossRef Morner S, Lindqvist P, Waldenstrom A, Kazzam E (2008) Right ventricular dysfunction in hypertrophic cardiomyopathy as evidenced by the myocardial performance index. Int J Cardiol 124:57–63PubMedCrossRef
16.
Zurück zum Zitat Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL et al (2009) Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 53:207–215PubMedCrossRef Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL et al (2009) Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 53:207–215PubMedCrossRef
17.
Zurück zum Zitat Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A et al (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238–248PubMedCrossRef Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A et al (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238–248PubMedCrossRef
18.
Zurück zum Zitat Patel N, Mills JF, Cheung MM (2009) Use of the myocardial performance index to assess right ventricular function in infants with pulmonary hypertension. Pediatr Cardiol 30:133–137PubMedCrossRef Patel N, Mills JF, Cheung MM (2009) Use of the myocardial performance index to assess right ventricular function in infants with pulmonary hypertension. Pediatr Cardiol 30:133–137PubMedCrossRef
19.
Zurück zum Zitat Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C et al (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119:408–416PubMedCrossRef Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C et al (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119:408–416PubMedCrossRef
20.
Zurück zum Zitat Rychik J (2010) Forty years of the Fontan operation: a failed strategy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 13:96–100PubMedCrossRef Rychik J (2010) Forty years of the Fontan operation: a failed strategy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 13:96–100PubMedCrossRef
21.
Zurück zum Zitat Sarkar H, Siddique MA, Haque KM, Ahmed CM, Mahmood M, Bhattacharjee B et al (2008) Evaluation of left ventricular global function using Doppler myocardial performance index in patients with systemic hypertension. Mymensingh Med J 17(Suppl):S65–S71PubMed Sarkar H, Siddique MA, Haque KM, Ahmed CM, Mahmood M, Bhattacharjee B et al (2008) Evaluation of left ventricular global function using Doppler myocardial performance index in patients with systemic hypertension. Mymensingh Med J 17(Suppl):S65–S71PubMed
22.
Zurück zum Zitat Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214–222PubMedCrossRef Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214–222PubMedCrossRef
23.
Zurück zum Zitat Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ et al (1995) New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function: a study in normals and dilated cardiomyopathy. J Cardiol 26:357–366PubMed Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ et al (1995) New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function: a study in normals and dilated cardiomyopathy. J Cardiol 26:357–366PubMed
24.
Zurück zum Zitat Tweddell JS, Nersesian M, Mussatto KA, Nugent M, Simpson P, Mitchell ME et al (2009) Fontan palliation in the modern era: factors impacting mortality and morbidity. Ann Thorac Surg 88:1291–1299PubMedCrossRef Tweddell JS, Nersesian M, Mussatto KA, Nugent M, Simpson P, Mitchell ME et al (2009) Fontan palliation in the modern era: factors impacting mortality and morbidity. Ann Thorac Surg 88:1291–1299PubMedCrossRef
25.
Zurück zum Zitat Zhang YQ, Sun K, Zhu SL, Wu LP, Chen GZ, Zhang ZF et al (2008) Doppler myocardial performance index in assessment of ventricular function in children with single ventricles. World J Pediatr 4:109–113PubMedCrossRef Zhang YQ, Sun K, Zhu SL, Wu LP, Chen GZ, Zhang ZF et al (2008) Doppler myocardial performance index in assessment of ventricular function in children with single ventricles. World J Pediatr 4:109–113PubMedCrossRef
26.
Zurück zum Zitat Zhang M, Takimoto E, Hsu S, Lee DI, Nagayama T, Danner T et al (2010) Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol 56:2021–2030PubMedCrossRef Zhang M, Takimoto E, Hsu S, Lee DI, Nagayama T, Danner T et al (2010) Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol 56:2021–2030PubMedCrossRef
Metadaten
Titel
Impact of Sildenafil on Echocardiographic Indices of Myocardial Performance After the Fontan Operation
verfasst von
David J. Goldberg
Benjamin French
Anita L. Szwast
Michael G. McBride
Bradley S. Marino
Nicole Mirarchi
Brian D. Hanna
Gil Wernovsky
Stephen M. Paridon
Jack Rychik
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Pediatric Cardiology / Ausgabe 5/2012
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-012-0196-9

Weitere Artikel der Ausgabe 5/2012

Pediatric Cardiology 5/2012 Zur Ausgabe

Images in Pediatric Cardiology

Rare Anomaly of Great Arteries

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.